Sihuan Pharmaceutical Recognized as a Leading Innovator in China's Pharmaceutical Industry

Hong Kong, October 14, 2023 - Sihuan Pharmaceutical Holdings Group Ltd. (HKEX stock code: 0460), a leading pharmaceutical company, is delighted to announce its selection as one of the first echelon of enterprises in "The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023."

The prestigious list, compiled by E Medicine Manager, evaluates pharmaceutical companies based on patent data from Derwent Innovation of Clarivate Analytics and Cortellis™ competitive intelligence and clinical trial data. Through a comprehensive analysis using a selection system encompassing "three dimensions and four indicators," the list aims to identify innovation power within the industry, share innovative experiences, and assess the innovation capacity and sustainability of China's pharmaceutical sector.

China's contribution to global pharmaceutical research and development has been on the rise, with authoritative data from 2018 showing that China's contribution reached 4%-8%, placing it second only to the United States and Japan. This achievement firmly establishes China's position in the second echelon of global pharmaceutical innovation and signals the advent of a golden age for Chinese pharmaceutical innovation.

Since 2019, E Medicine Manager has been selecting the "China's Top 100 Pharmaceutical Innovative Enterprises" annually to showcase the innovation strength of the country's pharmaceutical industry. The selection process involves model building, data collection and sorting, and evaluation based on four indicators: the number of authorized patents, the total number of patents applied, the number of clinical trials conducted, and the number of innovative drugs approved and launched. The evaluation considers three dimensions: innovation foundation, innovation process, and innovation achievements. This year marks the fifth year of the selection process.

The Top 100 innovative enterprises represent the forefront of China's pharmaceutical innovation capability and the core competitiveness of the industry. These companies play a pivotal role in driving the transformation and upgrading of China's pharmaceutical sector. Sihuan Pharmaceutical's inclusion in the first echelon of enterprises is a testament to its innovation strength, technical expertise, and sustainable innovation ability. It also recognizes the company's outstanding contributions to the development of the pharmaceutical industry.

Throughout this year, Sihuan Pharmaceutical and its subsidiaries have received positive news consistently. Several of their products have gained marketing approval, and significant progress has been made in clinical studies, with research results selected for prestigious international academic conferences. Looking ahead, Sihuan Pharmaceutical aims to continue innovating and developing more high-quality Chinese drugs, further promoting the growth and advancement of the pharmaceutical industry and serving the health and well-being of the population.

In conclusion, Sihuan Pharmaceutical's recognition as one of the leading innovators in China's pharmaceutical industry underscores its commitment to driving innovation and making significant contributions to the advancement of healthcare in the country. The company's inclusion in the first echelon of enterprises highlights its position as a key player in shaping the future of the industry and improving the lives of people through innovative pharmaceutical solutions.